HKD3.23
0.00% today
Hong Kong, Dec 30, 09:08 am CET
ISIN
KYG8167W1380
Symbol
1177
Sector
Industry

Sino Biopharmaceutical Target price 2024 - Analyst rating & recommendation

Sino Biopharmaceutical Classifications & Recommendation:

Buy
92%
Hold
8%

Sino Biopharmaceutical Price Target

Target Price HKD4.48
Price HKD3.23
Potential
Number of Estimates 9
9 Analysts have issued a price target Sino Biopharmaceutical 2025 . The average Sino Biopharmaceutical target price is HKD4.48. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 11 Analysts recommend Sino Biopharmaceutical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sino Biopharmaceutical stock has an average upside potential 2025 of . Most analysts recommend the Sino Biopharmaceutical stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Billion HKD 28.95 31.20
4.34% 7.76%
EBITDA Margin 25.87% 27.27%
1.13% 5.43%
Net Margin 8.87% 10.32%
8.53% 16.38%

7 Analysts have issued a sales forecast Sino Biopharmaceutical 2024 . The average Sino Biopharmaceutical sales estimate is

HKD31.2b
Unlock
. This is
7.57% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HKD31.7b 9.41%
Unlock
, the lowest is
HKD30.8b 6.14%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 HKD29.0b 4.34%
2024
HKD31.2b 7.76%
Unlock
2025
HKD34.2b 9.77%
Unlock
2026
HKD37.5b 9.40%
Unlock
2027
HKD31.1b 17.05%
Unlock
2028
HKD33.9b 9.16%
Unlock

5 Analysts have issued an Sino Biopharmaceutical EBITDA forecast 2024. The average Sino Biopharmaceutical EBITDA estimate is

HKD8.5b
Unlock
. This is
11.73% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HKD10.3b 34.95%
Unlock
, the lowest is
HKD7.0b 7.73%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 HKD7.5b 3.26%
2024
HKD8.5b 13.60%
Unlock
2025
HKD8.8b 3.92%
Unlock
2026
HKD10.0b 13.14%
Unlock

EBITDA Margin

2023 25.87% 1.13%
2024
27.27% 5.43%
Unlock
2025
25.81% 5.35%
Unlock
2026
26.70% 3.45%
Unlock

2 Sino Biopharmaceutical Analysts have issued a net profit forecast 2024. The average Sino Biopharmaceutical net profit estimate is

HKD3.2b
Unlock
. This is
17.00% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HKD3.9b 41.57%
Unlock
, the lowest is
HKD2.5b 7.57%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 HKD2.6b 12.50%
2024
HKD3.2b 25.36%
Unlock
2025
HKD2.7b 17.46%
Unlock
2026
HKD2.4b 9.00%
Unlock
2027
HKD2.5b 5.18%
Unlock
2028
HKD2.9b 12.55%
Unlock

Net Margin

2023 8.87% 8.53%
2024
10.32% 16.38%
Unlock
2025
7.76% 24.81%
Unlock
2026
6.45% 16.88%
Unlock
2027
8.18% 26.82%
Unlock
2028
8.44% 3.18%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share HKD 0.14 0.18
12.50% 28.57%
P/E 18.40
EV/Sales 2.10

2 Analysts have issued a Sino Biopharmaceutical forecast for earnings per share. The average Sino Biopharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

HKD0.18
Unlock
. This is
20.00% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
HKD0.21 40.00%
Unlock
, the lowest is
HKD0.14 6.67%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 HKD0.14 12.50%
2024
HKD0.18 28.57%
Unlock
2025
HKD0.14 22.22%
Unlock
2026
HKD0.13 7.14%
Unlock
2027
HKD0.14 7.69%
Unlock
2028
HKD0.16 14.29%
Unlock

P/E ratio

Current 21.81 21.24%
2024
18.40 15.64%
Unlock
2025
22.30 21.20%
Unlock
2026
24.50 9.87%
Unlock
2027
23.30 4.90%
Unlock
2028
20.70 11.16%
Unlock

Based on analysts' sales estimates for 2024, the Sino Biopharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.26 20.86%
2024
2.10 7.18%
Unlock
2025
1.91 8.90%
Unlock
2026
1.75 8.59%
Unlock
2027
2.11 20.56%
Unlock
2028
1.93 8.39%
Unlock

P/S ratio

Current 2.04 13.88%
2024
1.90 7.04%
Unlock
2025
1.73 8.90%
Unlock
2026
1.58 8.59%
Unlock
2027
1.91 20.56%
Unlock
2028
1.75 8.39%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today